

FDA approves pediatric treatment for Chagas disease

August 31 2017



(HealthDay)—Benznidazole has been approved by the U.S. Food and

Drug Administration to treat the tropical parasitic infection Chagas disease, in children aged 2 to 12.

In clinical testing, 55 to 60 percent of [pediatric patients](#) 6 to 12 years old treated with benznidazole had a negative antibody test for Chagas, the FDA said.

The most common side effects of the medication included [stomach pain](#), rash, weight loss, headache, nausea, and vomiting. More serious risks could include serious skin reactions, nervous system effects, and bone marrow depression.

"The FDA is committed to making available safe and effective therapeutic options to treat tropical diseases," Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research, said in a statement.

The drug is manufactured by Chemo Research S.L., based in Spain.

More information: [More Information](#)

[Health News](#) Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: FDA approves pediatric treatment for Chagas disease (2017, August 31) retrieved 24 April 2024 from

<https://medicalxpress.com/news/2017-08-fda-pediatric-treatment-chagas-disease.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
